Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

  • Chiotis, K.
  • Saint-Aubert, L.
  • Boccardi, M.
  • Gietl, A.
  • Picco, A.
  • Varrone, A.
  • Garibotto, V.
  • Herholz, K.
  • Nobili, F.
  • Nordberg, A.
  • Frisoni, Gb.
  • Winblad, B.
  • Jack CR, Jr.
ORKG logo View in ORKG
Publication date
January 2017
Publisher
Elsevier BV
ISSN
0197-4580
Citation count (estimate)
4

Abstract

The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent criteria, but some biomarkers have not been sufficiently investigated to justify their routine clinical use. Here, we evaluate in a literature review the clinical validity of amyloid positron emission tomography (PET) imaging using a structured framework developed for the assessment of oncological biomarkers. Homogenous criteria have been addressed in reviews of other Alzheimer's disease biomarkers. There is adequate evidence that the main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. The aims of phase 3 (early detection ability) have been partly achieved, while phase 4 studies (performance in representative mild co...

Extracted data

We use cookies to provide a better user experience.